Medication Development in Alcoholism: Suvorexant Versus Placebo
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The primary hypotheses under test are that alcohol dependent subjects treated with suvorexant
will report decreased craving for alcohol following alcohol exposure in the laboratory and
report significantly less drinking under naturalistic conditions, than those treated with
placebo.
Phase:
Phase 2
Details
Lead Sponsor:
The Scripps Research Institute
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)